Aerovate Therapeutics, Inc. (AVTE)

Aerovate Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-69.63	-75.52	-51.51	-22.96	-9.61
Depreciation & Amortization	0.28	0.1	0.07	0.02	0
Asset Writedown & Restructuring Costs	0.26	-	-	-	-
Loss (Gain) From Sale of Investments	-2.25	-3.06	-0.91	0.02	-
Stock-Based Compensation	11.31	11.91	5.48	2.04	0.06
Other Operating Activities	-	-	-	-	0.72
Change in Accounts Payable	-2.17	-0.16	1.37	0.61	0.04
Change in Other Net Operating Assets	-9	9.96	6.39	-7.12	0.94
Operating Cash Flow	-71.2	-56.78	-39.12	-27.4	-7.86
Capital Expenditures	-	-0.14	-0.2	-0.18	-
Investment in Securities	56.03	12.02	7.12	-113.25	-
Investing Cash Flow	56.03	11.88	6.93	-113.43	-
Short-Term Debt Issued	-	-	-	-	2.5
Total Debt Issued	-	-	-	-	2.5
Net Debt Issued (Repaid)	-	-	-	-	2.5
Issuance of Common Stock	25.73	46.23	0.77	126.95	0.01
Other Financing Activities	-0.31	-0.23	-0.37	-	-
Financing Cash Flow	25.43	46	0.4	190.46	8.92
Net Cash Flow	10.26	1.09	-31.8	49.62	1.06
Free Cash Flow	-71.2	-56.92	-39.32	-27.58	-7.86
Free Cash Flow Per Share	-2.49	-2.16	-1.61	-2.24	-32.44
Levered Free Cash Flow	-48.54	-28.72	-18.2	-18.78	-4.53
Unlevered Free Cash Flow	-48.54	-28.72	-18.2	-18.78	-4.48
Change in Net Working Capital	13.51	-10.3	-9.72	6.27	-1.01

Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q